Neurocritical care: Status epilepticus review

Critical Care Clinics

Volumn 30, Issue 4, 2014, Pages 751-764

  Al Mufti, Fawaz ^a   Claassen, Jan ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Continuous electroencephalogram monitoring; Convulsions; Intensive care unit; Nonconvulsive; Refractory status epilepticus; Status epilepticus; Treatment

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; ELECTROLYTE; KETAMINE; MIDAZOLAM; PROPOFOL; ANTICONVULSIVE AGENT; FOSPHENYTOIN SODIUM; PHENYTOIN;

DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; EMERGENCY WARD; EPILEPTIC STATE; HEART ARRHYTHMIA; HUMAN; INFECTION; KIDNEY FAILURE; LUNG DISEASE; PROGNOSIS; REVIEW; ADULT; AGED; ANALOGS AND DERIVATIVES; ELECTROENCEPHALOGRAPHY; EMERGENCY HEALTH SERVICE; FEMALE; INTENSIVE CARE; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PROCEDURES; STATUS EPILEPTICUS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BENZODIAZEPINES; CRITICAL CARE; ELECTROENCEPHALOGRAPHY; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; PRACTICE GUIDELINES AS TOPIC; STATUS EPILEPTICUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907986061     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2014.06.006     Document Type: Review

References (61)

1. Theodore W.H., Porter R.J., Albert P., et al. The secondarily generalized tonic-clonic seizure: a videotape analysis. Neurology 1994, 44(8):1403-1407.
2. Claassen J., Silbergleit R., Weingart S.D., et al. Emergency neurological life support: status epilepticus. Neurocrit Care 2012, 17(Suppl 1):S73-S78.
3. Pallin D.J., Goldstein J.N., Moussally J.S., et al. Seizure visits in US emergency departments: epidemiology and potential disparities in care. Int J Emerg Med 2008, 1(2):97-105.
4. Pitts S., Niska R.W., Xu J., et al. National Hospital Ambulatory Medical Care Survey: 2006 emergency department summary. Natl Health Stat Report 2008, 6(7):1-38.
5. Alldredge B.K., Gelb A.M., Isaacs S.M., et al. Acomparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. NEngl J Med 2001, 345(9):631-637.
6. Young G.B., Jordan K.G., Doig G.S. An assessment of nonconvulsive seizures in the intensive care unit using continuous EEG monitoring: an investigation of variables associated with mortality. Neurology 1996, 47(1):83-89.
7. Oddo M., Carrera E., Claassen J., et al. Continuous electroencephalography in the medical intensive care unit. Crit Care Med 2009, 37(6):2051-2056.
8. Mayer S.A., Claassen J., Lokin J., et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002, 59(2):205-210.
9. Brophy G.M., Bell R., Claassen J., et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012, 17(1):3-23.
10. Lowenstein D.H. Status epilepticus: an overview of the clinical problem. Epilepsia 1999, 40(Suppl 1):S3-S8. [discussion: S21-2].
11. Misra U.K., Kalita J., Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 2006, 67(2):340-342.
12. Moddel G., Bunten S., Dobis C., et al. Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus. JNeurol Neurosurg Psychiatry 2009, 80(6):689-692.
13. Albers J.M., Möddel G., Dittrich R., et al. Intravenous lacosamide-an effective add-on treatment of refractory status epilepticus. Seizure 2011, 20:428-430.
14. Kellinghaus C., Berning S., Immisch I., et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand 2011, 123(2):137-141.
15. Höfler J., Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia 2013, 54(3):393-404.
16. Goodwin H., Hinson H.E., Shermock K.M., et al. The use of lacosamide in refractory status epilepticus. Neurocrit Care 2011, 14:348-353.
17. Claassen J., Hirsch L.J., Emerson R.G., et al. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002, 43(2):146-153.
18. Fernandez A., Lantigua H., Lesch C., et al. High-dose midazolam infusion for refractory status epilepticus. Neurology 2014, 82(4):359-365.
19. Shafer A. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. Crit Care Med 1998, 26(5):947-956.
20. Igartua J., Silver P., Maytal J., et al. Midazolam coma for refractory status epilepticus in children. Crit Care Med 1999, 27(9):1982-1985.
21. Koul R.L., Raj Aithala G., Chacko A., et al. Continuous midazolam infusion as treatment of status epilepticus. Arch Dis Child 1997, 76(5):445-448.
22. Claassen J., Hirsch L.J., Emerson R.G., et al. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology 2001, 57(6):1036-1042.
23. Kam P.C., Cardone D. Propofol infusion syndrome. Anaesthesia 2007, 62(7):690-701.
24. Finley G.A., MacManus B., Sampson S.E., et al. Delayed seizures following sedation with propofol. Can J Anaesth 1993, 40(9):863-865.
25. Huff J.S., Bleck T.P. Propofol and midazolam in status epilepticus. Acad Emerg Med 1996, 3(2):179.
26. Bleck T. Critical care medicine: principles of diagnosis and management 1995, Mosby-Year Book, Chicago.
27. Yaffe K., Lowenstein D.H. Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus. Neurology 1993, 43(5):895-900.
28. Rossetti A.O., Milligan T.A., Vulliemoz S., et al. Arandomized trial for the treatment of refractory status epilepticus. Neurocrit Care 2011, 14(1):4-10.
29. Devlin E., Clarke R.S., Mirakhur R.K., et al. Effect of four I.V. induction agents on T-lymphocyte proliferations to PHA invitro. Br J Anaesth 1994, 73(3):315-317.
30. Pugin D., Foreman B., De Marchis G.M., et al. Is pentobarbital safe and efficacious in the treatment of super-refractory status epilepticus: a cohort study. Crit Care 2014, 18:R103.
31. Kramer A.H. Early ketamine to treat refractory status epilepticus. Neurocrit Care 2012, 16(2):299-305.
32. Zeiler F., Teitelbaum J., Gillman L.M. NMDA antagonists for refractory seizures. Neurocrit Care 2014, 20:502-513.
33. Martin B., Kapur J. Acombination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation. Epilepsia 2008, 49(2):248-255.
34. Hsieh C., Sung P.S., Tsai J.J., et al. Terminating prolonged refractory status epilepticus using ketamine. Clin Neuropharmacol 2010, 33(3):165-167.
35. Mewasingh L., Sékhara T., Aeby A., et al. Oral ketamine in paediatric non-convulsive status epilepticus. Seizure 2003, 12(7):483-489.
36. Naylor D.E., Liu H., Wasterlain C.G. Trafficking of GABAA receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. JNeurosci 2005, 25:7724-7733.
37. Meierkord H., Boon P., Engelsen B., et al. EFNS guideline on the management of status epilepticus. Eur J Neurol 2006, 13(5):445-450.
38. Prasad A., Worrall B.B., Bertram E.H., et al. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia 2001, 42(3):380-386.
39. Chen J.W., Wasterlain C.G. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006, 5(3):246-256.
40. Legriel S., Bruneel F., Dalle L., et al. Recurrent takotsubo cardiomyopathy triggered by convulsive status epilepticus. Neurocrit Care 2008, 9(1):118-121.
41. Legriel S., Azoulay E., Resche-Rigon M., et al. Functional outcome after convulsive status epilepticus. Crit Care Med 2010, 38(12):2295-2303.
42. Scholtes F.B., Renier W.O., Meinardi H. Generalized convulsive status epilepticus: causes, therapy, and outcome in 346 patients. Epilepsia 1994, 35(5):1104-1112.
43. Bleck T. Convulsive disorders: status epilepticus. Clin Neuropharmacol 1991, 14:191-198.
44. Mazarati A.M., Baldwin R.A., Sankar R., et al. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res 1998, 814(1-2):179-185.
45. Payne T., Bleck T.P. Status epilepticus. Crit Care Clin 1997, 13(1):17-38.
46. Claassen J., Lokin J.K., Fitzsimmons B.F., et al. Predictors of functional disability and mortality after status epilepticus. Neurology 2002, 58(1):139-142.
47. Novy J., Logroscino G., Rossetti A.O. Refractory status epilepticus: a prospective observational study. Epilepsia 2010, 51(2):251-256.
48. Logroscino G., Hesdorffer D.C., Cascino G., et al. Short-term mortality after a first episode of status epilepticus. Epilepsia 1997, 38(12):1344-1349.
49. DeLorenzo R., Pellock J.M., Towne A.R., et al. Epidemiology of status epilepticus. JClin Neurophysiol 1995, 12(4):316-325.
50. Shorvon S. Status epilepticus: its clinical features and treatment in children and adults 1994, Cambridge University Press, Cambridge (England).
51. Treiman D.M., Meyers P.D., Walton N.Y., et al. Acomparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. NEngl J Med 1998, 339(12):792-798.
52. Logroscino G., Hesdorffer D.C., Cascino G.D., et al. Long-term mortality after a first episode of status epilepticus. Neurology 2002, 58(4):537-541.
53. Krishnamurthy K.B., Drislane F.W. Depth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus. Epilepsia 1999, 40(6):759-762.
54. Stecker M.M., Kramer T.H., Raps E.C., et al. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia 1998, 39(1):18-26.
55. Rossetti A.O., Reichhart M.D., Schaller M.D., et al. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 2004, 45(7):757-763.
56. Koubeissi M., Alshekhlee A. In-hospital mortality of generalized convulsive status epilepticus: a large US sample. Neurology 2007, 69(9):886-893.
57. Rossetti A.O., Hurwitz S., Logroscino G., et al. Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. JNeurol Neurosurg Psychiatry 2006, 77(5):611-615.
58. Alvarez V., Januel J.M., Burnand B., et al. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia 2011, 52(7):1292-1296.
59. Lowenstein D.H., Alldredge B.K. Status epilepticus at an urban public hospital in the 1980s. Neurology 1993, 43(3 Pt 1):483-488.
60. Logroscino G., Hesdorffer D.C., Cascino G., et al. Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus. Epilepsia 2001, 42(8):1031-1035.
61. Hesdorffer D., Logroscino G., Cascino G.D., et al. Recurrence of afebrile status epilepticus in a population-based study in Rochester, Minnesota. Neurology 2007, 69(1):73-78.